All In Biotech

Drug Trial Radar · NCT05819359

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 273 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

273

Actual

Start

Mar 31, 2023

Primary completion

Apr 2, 2026

Study completion Sep 9, 2026

Sponsor

Lead sponsor
Bial R&D Investments, S.A.Industry
Sponsor type
Industry
First posted
Apr 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 35 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).

Conditions

  • Parkinson's Disease

Interventions

  • BIA 28-6156 10 mgDrug

    BIA 28-6156 10 mg, once daily, oral administration.

  • BIA 28-6156 60 mgDrug

    BIA 28-6156 60 mg, once daily, oral administration.

  • PlaceboDrug

    Placebo, once daily, oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from baseline to clinically meaningful progression on motor aspects of experiences of daily living (assessed by MDS-UPDRS Part II score and MDS-UPDRS Part III score)Time frame: From Baseline up to Week 78

Locations

95 sites in 11 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • University of California San Diego

    La Jolla, California

  • Cedars-Sinai

    Los Angeles, California

  • University of Colorado

    Aurora, Colorado

  • Parkinson's Center and Movement Disorders of Boca Raton

    Boca Raton, Florida

  • University of Miami, Dept. of Neurology

    Miami, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Morehouse School of Medicine

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Baylor University Medical Center

    Baltimore, Maryland

  • The Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Quest Research Institute, LLC

    Farmington Hills, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Struthers Parkinson's Center- East

    Saint Paul, Minnesota

  • Park Nicollet Struther's Parkinson's Center (Struthers Parkinsons Center at HealthPartners)

    Saint Paul, Minnesota

  • Robert Wood Johnson Medical School

    New Brunswick, New Jersey

  • Icahn School of Medicine at Mount Sinai Beth Israel

    New York, New York

  • Weil Cornell Medical Center

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Northwell Health Physician Partners

    New York, New York

  • Northwell Health

    New York, New York

  • University of Rochester Neurology

    Rochester, New York

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • University Hospitals Cleveland Medical Center

    South Euclid, Ohio

  • Univerity of Toledo

    Toledo, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Parkinson's Disease and Movement Disorders Cente at University of Pennyslvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • MUSC

    Charleston, South Carolina

  • Vanderbilt Medical Center

    Nashville, Tennessee

  • Baylor College of Medicine

    Houston, Texas

  • University of Texas Health Science Center - San Antonio

    San Antonio, Texas

  • Intermountain Healthcare

    Salt Lake City, Utah

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.